Vaccination represents the most efficient tool to control morbidity and mortality resulting from influenza infections in humans. The currently licensed influenza vaccines provide good protection levels in healthy adults, whereas lower protection is generally achieved in ageing individuals who are at a higher risk of developing severe clinical manifestations. Future improvements in influenza vaccines should address the needs of high risk groups including the elderly, small children and chronic patients. Recently, due to the increased incidence of avian influenza pandemic outbreaks, the prevention of a potential human influenza pandemic turned into another crucial issue in the influenza vaccination field. The development and validation of manufacturing processes for efficient and safe pandemic vaccines became one of the top priorities of health, regulatory and funding agencies all over the world. In the pandemic context, the development of novel vaccines administered via the mucosal route may playa significant role by reducing virus shedding from infected individuals. This chapter provides insights in the limitations of existing manufacturing processes, new approaches to overcome limitation in vaccine production, mechanisms of action of current vaccines and discuss potential strategies to improve the immunogenicity and efficacy of influenza vaccines. © 2009 Landes Bioscience and Springer Sciences-Business Media.
CITATION STYLE
Fichera, E., Felnerova, D., Mischler, R., Viret, J. F., & Glueck, R. (2009). New strategies to overcome the drawbacks of currently available flu vaccines. Advances in Experimental Medicine and Biology, 655, 243–252. https://doi.org/10.1007/978-1-4419-1132-2_15
Mendeley helps you to discover research relevant for your work.